Fullmektig i Norge:
Fullmektig i EP:
2015.02.16, AU 2015900507
ABOU OUF A A ET AL: "THIOPHENE SULPHONYLUREAS STRUCTURALLY RELATED TO ANTIDIABETIC DRUGS", JOURNAL OF DRUG RESE, DRUG RESEARCH AND CONTROL CENTER, GIZA, EG, vol. 6, no. 2, 1 January 1974 (1974-01-01) , pages 123-129, XP009011580, ISSN: 0368-1866 (B1)
YOUSSEF, K ET AL.: 'Synthesis of certain diarylsulfonylureas as antitumor agents' MEDICINAL CHEMISTRY RESEARCH vol. 10, no. 6, 2001, pages 404 - 418, XP008020857 (B1)
DATABASE REGISTRY [Online] 19 December 2000 'N-[[(4- chlorophenyl)amino]carbonyl]-1-(phenylmethy l)-1H-1,2,4-Triazole-3-sulfonamide', XP055475050 Retrieved from STN Database accession no. 309742-96-9 (B1)
EGGLER J F ET AL: "Synthesis of covalent (14C)-labeled diarylsulfonylurea (DASU) inhibitors of the processing and release of IL-1", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, JOHN WILEY, GB, vol. 45, no. 9, 1 August 2002 (2002-08-01) , pages 785-794, XP002264662, ISSN: 0362-4803, DOI: 10.1002/JLCR.602 (B1)
EP-A1- 0 885 890 (B1)
EP-A1- 1 236 468 (B1)
FOROUMADI, A ET AL.: 'Synthesis of certain diarylsulfonylurea derivatives as new potential antitumor agents' CHEMISTRY: AN INDIAN JOURNAL vol. 1, no. 12, 2005, pages 745 - 748, XP009505510 (B1)
FRANK J. URBAN ET AL: "Novel Synthesis of 1-(1,2,3,5,6,7-Hexahydro- s -indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-et hyl)-furan-2-sulfonyl]urea, an Anti-inflammatory Agent", SYNTHETIC COMMUNICATIONS, vol. 33, no. 12, 1 July 2003 (2003-07-01), pages 2029-2043, XP55306651, PHILADELPHIA, PA; US ISSN: 0039-7911, DOI: 10.1081/SCC-120021029 (B1)
GODA, F ET AL.: 'Development of some 1,2,4-triazole derivatives as potential hypoglycemic agents' ALEXANDRIA JOURNAL OF PHARMACEUTICAL SCIENCES vol. 1, no. 2, 1987, pages 63 - 66, XP009505505 (B1)
HOWBERT J J ET AL: "NOVEL AGENTS EFFECTIVE AGAINST SOLID TUMORS: THE DIARYLSULFONYLUREAS. SYNTHESIS, ACTIVITIES, AND ANALYSIS OF QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 33, 1 January 1990 (1990-01-01), pages 2393-2407, XP000919053, ISSN: 0022-2623, DOI: 10.1021/JM00171A013 (B1)
MOHAMADI, F. ET AL.: 'Sulfonylureas: A New Class of Cancer Chemotherapeutic Agents' JOURNAL OF MEDICINAL CHEMISTRY vol. 35, 1992, pages 3012 - 3016, XP000919054 (B1)
US-A- 4 018 929 (B1)
US-A- 5 169 860 (B1)
WO-A1-01/19390 (B1)
WO-A1-98/32733 (B1)
DATABASE REGISTRY [Online] 15 March 2004 'N-(2-chlorophenyl)-5-[[[[(2- chlorophenyl)amino] carbonyl] amino] sulfonyl]-1H-1,2,4-Triazole-1-carboxamide', XP055475046 Retrieved from STN Database accession no. 663215-37-0 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP3259253)
|
Innkommende
Korrespondanse (Hovedbrev inn)
|
Utgående
EP defect letter
|
Innkommende
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Neste fornyelse/årsavgift:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 10. avg. år (EP) | 2025.01.23 | 4160 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 9. avg. år (EP) | 2024.01.25 | 2850 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 8. avg. år (EP) | 2023.01.27 | 2550 | MASTER DATA CENTER INC | Betalt og godkjent |
Årsavgift 7. avg. år (EP) | 2022.01.27 | 2200 | MASTER DATA CENTER INC | Betalt og godkjent |
Årsavgift 6. avg. år (EP) | 2021.02.19 | 2000 | 1/DENNEMEYER CO S.A R.L. | Betalt og godkjent |
32005784 expand_more expand_less | 2020.05.26 | 5500 | Budde Schou A/S | Betalt |
Valideringsgebyr EP-patent
5500 = 1 X 5500
|
||||
Årsavgift 5. avg. år (EP) | 2020.03.12 | 1650 | 1/DENNEMEYER CO S.A R.L. | Betalt og godkjent |